56 results
424B3
EVOK
Evoke Pharma Inc
14 Mar 24
Prospectus supplement
6:44pm
for assessing and managing our material risks from cybersecurity threats. The team has primary responsibility for our overall cybersecurity risk … not include any adjustments that might result from the outcome of this uncertainty.
Basis for Opinion
These financial statements are the responsibility
8-K
EX-1.1
dm00qfm3
9 Feb 24
Evoke Pharma Announces Pricing of Underwritten Public Offering of up to $30 Million
5:15pm
424B4
k49g8i osrn
9 Feb 24
Prospectus supplement with pricing info
5:14pm